AMRX vs C · P/E 44, rev $2.79B vs P/E 16, rev $85.22B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the AMRX and C stock pages for the full models.
Not investment advice.